Also, there were more patients who were treated with drugs that raise glomerular hydrostatic pressure (e.g., dihydropyridine calcium‐channel blockers, direct‐acting smooth muscle relaxants, potassium channel agonists, b‐2‐adrenergic receptor agonist, erythropoietin, and endothelin receptor antagonist) among those who developed WRN as compared to the non‐WRN group. This evidence concerns the gene EPO and Werner syndrome.